Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have received an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $50.00.

ZLAB has been the topic of several recent analyst reports. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Cantor Fitzgerald cut their price target on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Zacks Research cut shares of Zai Lab from a “hold” rating to a “strong sell” rating in a report on Friday, January 23rd. UBS Group initiated coverage on shares of Zai Lab in a report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st.

Insider Transactions at Zai Lab

In related news, CEO Ying Du sold 5,576 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total value of $113,694.64. Following the sale, the chief executive officer directly owned 1,125,279 shares of the company’s stock, valued at $22,944,438.81. This represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard Gaynor bought 1,731 shares of the stock in a transaction on Tuesday, March 17th. The shares were acquired at an average price of $18.91 per share, with a total value of $32,733.21. Following the purchase, the director owned 56,630 shares of the company’s stock, valued at $1,070,873.30. The trade was a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 36,925 shares of company stock valued at $741,239 over the last ninety days. 4.96% of the stock is currently owned by corporate insiders.

Institutional Trading of Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. SG Americas Securities LLC raised its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. Institutional investors own 41.65% of the company’s stock.

Zai Lab Trading Up 2.4%

NASDAQ ZLAB opened at $21.00 on Wednesday. The company’s fifty day simple moving average is $18.81 and its 200-day simple moving average is $21.51. Zai Lab has a 52 week low of $15.96 and a 52 week high of $44.34. The stock has a market cap of $2.37 billion, a P/E ratio of -13.04 and a beta of 0.86.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. The company had revenue of $127.60 million during the quarter. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. On average, research analysts expect that Zai Lab will post -2.58 EPS for the current fiscal year.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.